| Document and Entity Information | 12 Months Ended |
| Dec. 31, 2022 | |
| Cover [Abstract] | |
| Document Type | DEF 14A |
| Amendment Flag | false |
| Entity Registrant Name | SIGA Technologies, Inc. |
| Entity Central Index Key | 0001010086 |
| Pay vs Performance Disclosure - USD ($) | 12 Months Ended | ||
| Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
| Pay vs Performance Disclosure [Table] | |||
| Pay vs Performance [Table Text Block] | PAY VERSUS PERFORMANCE In accordance with Item 402(v) of Regulation S-K, the Company is required to disclose pay versus performance by comparing compensation amounts previously reported for the last three calendar years to the SEC’s definition of “Compensation Actually Paid” for such years. Also as required by the SEC, this section compares Compensation Actually Paid to various measures used to gauge performance at SIGA. Compensation Actually Paid is a required disclosure item, the amount of which is calculated in accordance with SEC rules. Such measure was not incorporated into the philosophy and strategy of compensation-setting set forth in the “Compensation Discussion and Analysis” of this proxy statement. Pay Versus Performance Table Year Summary Compensation Table Total for PEO 1 Compensation Actually Paid to PEO ,2 Average Summary Compensation Table Total for Non-PEO Named Executive Officers 3 Average Compensation Actually Paid to Non-PEOs Named Executive Officers 4, Value of initial fixed $100 investment based on: Net Income International Sales Revenue 6 Total Shareholder Return Peer Group Total Shareholder Return 5 2022 $1,738,912 $1,738,912 $ 993,871 $ 993,871 $174 $ 111 $33,904,806 $70,971,722 2021 $1,688,264 $1,688,264 $1,285,045 $1,269,045 $158 $125 $69,450,766 $13,014,160 2020 $1,639,090 $1,639,090 $1,280,950 $1,354,729 $152 $126 $56,342,010 $ 2,542,823 (1) Amount included here is the amount in the “Total” column from the Summary Compensation Table (“SCT”) for the principal executive officer (“PEO”) for the applicable year. (2) “Compensation Actually Paid” is calculated by starting with the amounts reported for the PEO in the “Total” column of the SCT for the applicable year, with such amounts adjusted for stock based compensation. The PEO received no stock based compensation during the years presented. (3) Amount included here is the average of the amounts in the “Total” column from the SCT for the applicable year for each of the other NEOs. 2022 amount impacted by the resignation of Ms. Abrams, effective April 18, 2022. (4) In accordance with the requirements of Item 402(v) of Regulation S-K, the following adjustments were made to Average Total Compensation for the NEOs as a group for each year to determine the compensations “actually paid”. Year Reported Summary Compensation Table for Non-PEO NEOs Average Reported Value of Equity Awards Total Average Equity Award Adjustments (a) Average Compensation “Actually Paid” to Non-PEO NEOs 2022 $ 993,871 — — $ 993,871 2021 $1,285,045 — $(16,000) $1,269,045 2020 $1,280,950 — $ 73,779 $1,354,729 a) The amounts added or deducted in calculating the total average equity award adjustments are as follows: Year Grant Date Fair Value of Equity Awards Granted During Applicable Year Year-End Fair Value of Equity Awards Granted During Applicable Year Change in Fair Value as of Year-End of Any Prior Year Awards that Remain Unvested as of Year-End Change in Fair Value as of the Vesting Date of Any Prior Year Awards that Vested During Applicable Year Total Equity Value Reflected in Compensation Actually Paid 2022 — — — — — 2021 — — — $(16,000) $(16,000) 2020 — — $44,445 $ 29,334 $ 73,779 (5) The peer group, for purposes of this analysis, is the Nasdaq Biotechnology Index. The company’s stock performance relative to the Nasdaq Biotechnology Index is disclosed in the Company’s Form 10-K. (6) International sales revenue is a financial measure that is consistent with U.S. GAAP that is considered by the Company as part of its executive compensation program. The Compensation Committee reviews a variety of performance goals and metrics for the purpose of awarding compensation to executive officers that are consistent with the Company’s overall compensation philosophy and the long-term interests of its shareholders. Among these, the Compensation Committee has identified international sales as the most important financial performance measure (that is not otherwise required to be disclosed in the table above) used by the Company to link compensation actually paid to its NEOs for the year ended December 31, 2022 to the Company’s performance. | ||
| Company Selected Measure Name | International sales revenue | ||
| Named Executive Officers, Footnote [Text Block] | (3) Amount included here is the average of the amounts in the “Total” column from the SCT for the applicable year for each of the other NEOs. 2022 amount impacted by the resignation of Ms. Abrams, effective April 18, 2022. | ||
| Peer Group Issuers, Footnote [Text Block] | (5) The peer group, for purposes of this analysis, is the Nasdaq Biotechnology Index. The company’s stock performance relative to the Nasdaq Biotechnology Index is disclosed in the Company’s Form 10-K. | ||
| PEO Total Compensation Amount | $ 1,738,912 | $ 1,688,264 | $ 1,639,090 |
| PEO Actually Paid Compensation Amount | 1,738,912 | 1,688,264 | 1,639,090 |
| Non-PEO NEO Average Total Compensation Amount | 993,871 | 1,285,045 | 1,280,950 |
| Non-PEO NEO Average Compensation Actually Paid Amount | $ 993,871 | 1,269,045 | 1,354,729 |
| Adjustment to Non-PEO NEO Compensation Footnote [Text Block] | (4) In accordance with the requirements of Item 402(v) of Regulation S-K, the following adjustments were made to Average Total Compensation for the NEOs as a group for each year to determine the compensations “actually paid”. Year Reported Summary Compensation Table for Non-PEO NEOs Average Reported Value of Equity Awards Total Average Equity Award Adjustments (a) Average Compensation “Actually Paid” to Non-PEO NEOs 2022 $ 993,871 — — $ 993,871 2021 $1,285,045 — $(16,000) $1,269,045 2020 $1,280,950 — $ 73,779 $1,354,729 a) The amounts added or deducted in calculating the total average equity award adjustments are as follows: Year Grant Date Fair Value of Equity Awards Granted During Applicable Year Year-End Fair Value of Equity Awards Granted During Applicable Year Change in Fair Value as of Year-End of Any Prior Year Awards that Remain Unvested as of Year-End Change in Fair Value as of the Vesting Date of Any Prior Year Awards that Vested During Applicable Year Total Equity Value Reflected in Compensation Actually Paid 2022 — — — — — 2021 — — — $(16,000) $(16,000) 2020 — — $44,445 $ 29,334 $ 73,779 | ||
| Compensation Actually Paid vs. Total Shareholder Return [Text Block] | The relationship between (1) compensation actually paid to the PEO and the average of compensation actually paid to NEOs other than the PEO and (2) cumulative total shareholder return on the common stock of the Company and cumulative total shareholder return on the stock of NASDAQ Biotech Composite Index for the last three completed fiscal years is shown in Figure 1. Figure 1: Compensation Actually Paid versus Total Shareholder Return (“TSR”) | ||
| Compensation Actually Paid vs. Net Income [Text Block] | The relationship between (1) compensation actually paid to the PEO and the average of compensation actually paid to NEOs other than the PEO and (2) net income of the Company for the last three completed fiscal years is shown in Figure 2. Figure 2: Compensation Actually Paid versus Net Income | ||
| Compensation Actually Paid vs. Company Selected Measure [Text Block] | The relationship between (1) compensation actually paid to the PEO and the average of compensation actually paid to NEOs other than the PEO and (2) international sales revenue of the Company for the last three completed fiscal years is shown in Figure 3. Figure 3: Compensation Actually Paid versus International Sales Revenue | ||
| Total Shareholder Return Vs Peer Group [Text Block] | The relationship between (1) compensation actually paid to the PEO and the average of compensation actually paid to NEOs other than the PEO and (2) cumulative total shareholder return on the common stock of the Company and cumulative total shareholder return on the stock of NASDAQ Biotech Composite Index for the last three completed fiscal years is shown in Figure 1. Figure 1: Compensation Actually Paid versus Total Shareholder Return (“TSR”) | ||
| Tabular List [Table Text Block] | List of Performance Measures The Company utilizes other important financial measures to consider for compensation actually paid to its NEOs performance as set forth in the table below. Most Important Performance Measures International Sales Revenue Total Product Sales and Supportive Services Revenues Total Revenues Operating Income Net Income Diluted Earnings per Share Relative TSR | ||
| Total Shareholder Return Amount | $ 174 | 158 | 152 |
| Peer Group Total Shareholder Return Amount | 111 | 125 | 126 |
| Net Income (Loss) | $ 33,904,806 | $ 69,450,766 | $ 56,342,010 |
| Company Selected Measure Amount | 70,971,722 | 13,014,160 | 2,542,823 |
| Measure [Axis]: 1 | |||
| Pay vs Performance Disclosure [Table] | |||
| Measure Name | International Sales Revenue | ||
| Measure [Axis]: 2 | |||
| Pay vs Performance Disclosure [Table] | |||
| Measure Name | Total Product Sales and Supportive Services Revenues | ||
| Measure [Axis]: 3 | |||
| Pay vs Performance Disclosure [Table] | |||
| Measure Name | Total Revenues | ||
| Measure [Axis]: 4 | |||
| Pay vs Performance Disclosure [Table] | |||
| Measure Name | Operating Income | ||
| Measure [Axis]: 5 | |||
| Pay vs Performance Disclosure [Table] | |||
| Measure Name | Net Income | ||
| Measure [Axis]: 6 | |||
| Pay vs Performance Disclosure [Table] | |||
| Measure Name | Diluted Earnings per Share | ||
| Measure [Axis]: 7 | |||
| Pay vs Performance Disclosure [Table] | |||
| Measure Name | Relative TSR | ||
| Non-PEO NEO [Member] | Average Reported Value of Equity Awards [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | $ 0 | $ 0 | $ 0 |
| Non-PEO NEO [Member] | Total Equity Value Reflected in Compensation Actually Paid [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | 0 | (16,000) | 73,779 |
| Non-PEO NEO [Member] | Grant Date Fair Value of Equity Awards Granted During Applicable Year [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | 0 | 0 | 0 |
| Non-PEO NEO [Member] | Year-End Fair Value of Equity Awards Granted During Applicable Year [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | 0 | 0 | 0 |
| Non-PEO NEO [Member] | Change in Fair Value as of Year-End of Any Prior Year Awards that Remain Unvested as of Year-End [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | 0 | 0 | 44,445 |
| Non-PEO NEO [Member] | Change in Fair Value as of the Vesting Date of Any Prior Year Awards that Vested During Applicable Year [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | $ 0 | $ (16,000) | $ 29,334 |
